Mortality in Korean Patients With Rheumatoid Arthritisopen access
- Authors
- Lee, Yeon-Kyung; Bae, Sang-Cheol
- Issue Date
- Jul-2021
- Publisher
- 대한류마티스학회
- Keywords
- Rheumatoid arthritis; Mortality; Republic of Korea
- Citation
- 대한류마티스학회지, v.28, no.3, pp.113 - 118
- Indexed
- SCOPUS
KCI
- Journal Title
- 대한류마티스학회지
- Volume
- 28
- Number
- 3
- Start Page
- 113
- End Page
- 118
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/141531
- DOI
- 10.4078/jrd.2021.28.3.113
- ISSN
- 2093-940X
- Abstract
- Rheumatoid arthritis (RA) is a chronic inflammatory disease in which the abnormal immune system causes arthritis. We reviewed previous studies about the mortality and causes of death in Korean patients with RA. Also, we discussed the association between comorbidities and mortality in Korean patients with RA. In Korea, a few epidemiologic studies reporting mortality rates in patients with RA have been conducted using large databases. According to these data sources, the estimated mortality rate of Korean patients with RA from 1.29% to 1.65%. Despite substantial improvements in RA management, the mortality rate of patients with RA remains higher than that of the general population. Also, the most common cause of death was malignancy, and respiratory disease and cardiovascular disease followed. The malignancy-specific mortality rate of patient with RA was not higher than that of the general population; however, several causes of death, such as respiratory disease and infections, were associated with a higher mortality rate among patients with RA than among the general population. Therefore, to increase the survival rate of patients with RA, attention should be paid to the management of comorbidities as well as to the RA itself.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/141531)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.